BBOT · BridgeBio Oncology Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Bihua Chen Chairperson and CEO | ▼ Sell | Other | 6,083,221 Shares held | 7/1/2026 | View profile |
| Helix Holdings II LLC Director | ▲ Buy | Grant | 509,000 Shares held | 2/13/2024 | View profile |
| Yong Ben Chief Med & Dev Officer | ▼ Sell | Tax Withholding | 44,576 Shares held | 7/1/2026 | View profile |
| Beltran Pedro Chief Scientific Officer | ▼ Sell | Tax Withholding | 44,576 Shares held | 7/1/2026 | View profile |
| Mark C. McKenna | ▲ Buy | Option Exercise | 30,000 Shares held | 8/11/2025 | View profile |
| John P. Schmid Director | ▲ Buy | Option Exercise | 30,000 Shares held | 8/11/2025 | View profile |
| Holman Albert A III | ▲ Buy | Option Exercise | 30,000 Shares held | 8/11/2025 | View profile |
| Mehra Uneek Chief Financial Officer | ▼ Sell | Tax Withholding | 22,806 Shares held | 4/1/2026 | View profile |
| Elmelech Idan COO & Principal Financial Ofcr | ▼ Sell | Tax Withholding | 14,495 Shares held | 7/1/2026 | View profile |
| Cobo Marc Principal Accounting Officer | ▼ Sell | Tax Withholding | 14,141 Shares held | 9/10/2026 | View profile |
Transaction History
| Cobo Marc | ▲ Buy | Grant | 9,038 | $0 | 9/10/2026 |
| Cobo Marc | ▼ Sell | Tax Withholding | 203 | $1K | 9/10/2026 |
| Cobo Marc | ▼ Sell | Tax Withholding | 125 | $975 | 7/1/2026 |
| Elmelech Idan | ▼ Sell | Tax Withholding | 343 | $3K | 7/1/2026 |
| Yong Ben | ▼ Sell | Tax Withholding | 1,047 | $8K | 7/1/2026 |
| Beltran Pedro | ▼ Sell | Tax Withholding | 1,047 | $8K | 7/1/2026 |
| Bihua Chen | ▼ Sell | Other | 4,528,186 | $0 | 7/1/2026 |
| Bihua Chen | ▼ Sell | Other | 1,704,862 | $0 | 7/1/2026 |
| Bihua Chen | ▼ Sell | Other | 130,865 | $0 | 7/1/2026 |
| Bihua Chen | ▼ Sell | Other | 2,692,459 | $0 | 7/1/2026 |
| Beltran Pedro | ▼ Sell | Tax Withholding | 1,047 | $9K | 4/1/2026 |
| Mehra Uneek | ▼ Sell | Tax Withholding | 524 | $5K | 4/1/2026 |
| Yong Ben | ▼ Sell | Tax Withholding | 1,047 | $9K | 4/1/2026 |
| Yong Ben | ▲ Buy | Grant | 46,670 | $0 | 3/10/2026 |
| Beltran Pedro | ▲ Buy | Grant | 46,670 | $0 | 3/10/2026 |
| Mehra Uneek | ▲ Buy | Grant | 23,330 | $0 | 3/10/2026 |
| Bihua Chen | ▲ Buy | Option Exercise | 4,172,126 | — | 8/11/2025 |
| Bihua Chen | ▼ Sell | Other | 152,940 | $0 | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 760,496 | $8.2M | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 639,110 | $6.8M | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 5,598,425 | $60.0M | 8/11/2025 |
| Holman Albert A III | ▲ Buy | Option Exercise | 30,000 | — | 8/11/2025 |
| Mark C. McKenna | ▲ Buy | Option Exercise | 30,000 | — | 8/11/2025 |
| John P. Schmid | ▲ Buy | Option Exercise | 30,000 | — | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 1,762,760 | — | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 1,905,046 | — | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 284,571 | — | 8/11/2025 |
| Bihua Chen | ▲ Buy | Grant | 509,000 | $5.1M | 2/13/2024 |
| Bihua Chen | ▲ Buy | Open Market | 69,360 | $694K | 2/13/2024 |
| Bihua Chen | ▲ Buy | Open Market | 1,427,040 | $14.3M | 2/13/2024 |
| Bihua Chen | ▲ Buy | Open Market | 903,600 | $9.0M | 2/13/2024 |
| Helix Holdings II LLC | ▲ Buy | Grant | 509,000 | $5.1M | 2/13/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4)
BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4). BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.